title: Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
abstract: Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.
authors.affiliation: Department of Neurology, University of Kansas Medical Center, Kansas City 66103.
authors.forename: W C
authors.initials: WC
authors.lastname: Koller
authors.forename: G A
authors.initials: GA
authors.lastname: Block
authors.forename: J E
authors.initials: JE
authors.lastname: Ahlskog
authors.forename: S
authors.initials: S
authors.lastname: Ahrens
authors.forename: J M
authors.initials: JM
authors.lastname: Cedarbaum
authors.forename: G
authors.initials: G
authors.lastname: Cyhan
authors.forename: C G
authors.initials: CG
authors.lastname: Goetz
authors.forename: P A
authors.initials: PA
authors.lastname: LeWitt
authors.forename: C
authors.initials: C
authors.lastname: Liss
authors.forename: L
authors.initials: L
authors.lastname: McLean
mesh_terms: D000368:Aged; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007785:Lactose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D010078:Oxazines; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D003692:Delayed-Action Preparations; D010078:Oxazines; D008747:Methylcellulose; C071191:MK 458; D007785:Lactose